icon

Antigenics announced on Monday the expansion of an ongoing Phase II glioma trial for Oncophage (vitespen/HSPPC-96). The trial will enroll up to fifty patients and will be expanded based on the encouraging safety and survival results seen so far.

Oncophage is a personalized cancer vaccine, meaning a s...

Read more

Shares of CellDex Thereapeutics were slammed late last week after Pfizer backed out of an over two-year-old licensing agreement for CDX-110, a cancer vaccine currently being tested for effectiveness in fighting one of the most aggressive forms of brain cancer.  CDX-110 is CellDex's most advanced pr...

Read more